Optibiotix Health Share Discussion Threads

[kreature] 29/11/2020 13:40

Manc, is it hot out there this time of year?

[kreature] 29/11/2020 13:34

Did 5000 boxes get ordered before end Nov ? Is it worth RNS ing that with a placing next week to pay for it all, to be prudent ?

[manc10] 29/11/2020 12:19

mr ukog where have you been hiding raytard...
some one said you have been hiding in one of ukogs wells . they say its cold but the driest place on earth woooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooow

[sentiment riles] 29/11/2020 11:27

Well can only go on what I’ve seen audited to date. Best to look forward again I think as is the annual habit

Might be positive again January to May 2021 ?

Then when the audited comes out, we can focus on H2 again to December 2021

You know how it is

Anyway I’m near finished analysing opti

Decided to pass it on to somebody far more credible haha

[rayrac] 29/11/2020 11:23

Cash too..they are preparing the ground for a raise somehow? Better block out online trading and h&b sales. They look dire from here. 4 years online and 5k+ sales and top shelf, back of store at h&b.

If they can’t get sales going in the UK, they must be struggling elsewhere?!

[sentiment riles] 29/11/2020 11:21

Anyway is there any clarification on any of the 79 agreements deemed part of the expected 1/3 fail?

Or are they all still to be considered valid by market?

[sentiment riles] 29/11/2020 11:18

It may trigger a contract. So maybe a pretty contract agreement that sets out contract terms if x or y is done

But then the client just needn’t fulfil the agreement so just got to call it “a phone call”

[sentiment riles] 29/11/2020 11:15

Well they did mention a “contract̶1; somewhere for a recent one. Or news outlet did. Il look later But then it is only valid if minimums are ordered or somethings so, not really a contract then. It’s an agreement

[rayrac] 29/11/2020 11:14

Btw, it’s contracts they need surely, not agreements?

[sentiment riles] 29/11/2020 09:35

Have any of the agreements where Opti said 1/3 could possibly fail, been highlighted yet? Or is it still officially 79 deals being ‘recognised217; ?

[sentiment riles] 29/11/2020 09:32

andddd, home again

Slarty does not like to discuss things here

So here is where I discuss...

[kreature] 29/11/2020 08:50

NDA on consumers ? Will there be impairments, write offs, whatever u call em?

A write-off is a ‘derecognition event’ of course

[sentiment riles] 29/11/2020 00:42

I thought it was just me

As soon as i read it

It connected in Bowlatory terms

[kreature] 29/11/2020 00:36

Thank you for your regular bowel movement of science. Two words to take away from that are, stool consistency

[manc10] 29/11/2020 00:23

Seed Health email.

Still in Search of Better Poop?

You’re not alone. 61% of Americans suffer from digestive issues, including constipation, bloating, and irregularity1. And some 50 million live with chronic constipation2.

We’re talking about straining, hard stools, wanting to go but can’t, abdominal discomfort, feeling like you haven’t quite finished, and spending way too much time on the toilet.

So, why is pooping so complicated? Much of what we do contributes to our digestive health: what and when we eat, our hydration, how much (soluble and insoluble) fiber we get, our response to stress and anxiety, the quality and duration of our sleep, how much exercise we get, and our indulgence in choices like caffeine and alcohol.

While lifestyle and dietary choices are important, specific probiotics can also have a meaningful impact on your digestion—read: better poops.

What people ask us most is, “but how do probiotics actually work and how do I know which one to take?”

Probiotic strains have been studied extensively in clinical trials to support digestion and gastrointestinal function. But choosing the right strains (not just the species) requires precision. The delivery can matter. The dosage matters. And the quality of the evidence supporting the claims matters.

We’re working to set a new standard in probiotics—one that adheres to the scientific definition that was defined by a UN/WHO expert panel chaired by our Seed Chief Scientist, Dr. Gregor Reid in 2001.

The quick translation? A probiotic is a microorganism that is alive and administered in the dosage clinically studied to confer a health benefit in the host (that’s you!)

Formulated to adhere to this scientific definition, Seed’s DS-01TM Daily Synbiotic is an Evidence-Based Prebiotic and Probiotic Formulated for Systemic Benefits—including Digestive Health (i.e. Your Poops)

Let’s break it down:

1. A probiotic must be alive. Engineered in our ViaCapTM 2-in-1 capsule delivery technology, our probiotic inner capsule is nested inside a prebiotic outer capsule, protecting the bacteria from oxygen, moisture, heat, light, and stomach acid.

This technology delivers our probiotic strains—100% alive and well—to the end of the small intestine, to then be delivered into the colon, where they can offer digestive health benefits. (Proven in our SHIME® survivability testing).

2. A probiotic must be administered in a clinically studied dosage. The recommended daily dose of the Daily Synbiotic contains 53.6 Billion AFU for 2 capsules per day. This is based on the dosages studied for each strain in their respective clinical trial, which demonstrated conferred benefits. Probiotic organisms do not enter into systemic circulation so there is no need to adjust the dose based on body size or weight.

Every body is physiologically unique and you know your body best—it is entirely possible that you would still experience benefits at a lower dosage—however, we are unable to say for certain as we have not conducted studies to obtain clinical data at a lower dose.

We recommend trying to find a routine that works best for you and is best suited for your body. Consistent daily intake is most important.

3. A probiotic must confer a health benefit in the host. In a 300-person study3, researchers also discovered that two specific strains (Lactobacillus plantarum SD-LP1-IT and Bifidobacterium breve SD-BR3-IT) found in the Daily Synbiotic formulation supported gastrointestinal functions in people with digestive issues:

Bowel movement regularity
Stool consistency
Ease of expulsion
Bowel movement comfort
Abdominal bloating
In other words, sh*t got done 🤓 💩

That's because these bacteria perform critical functions like the production of short-chain fatty acids (particularly acetate, propionate, and butyrate) that support wave-like muscle contractions in the intestines in order to move poop out and into the toilet.

As a company, we have never had a promotional sale, but we know this 2020 holiday season, health is top of mind for everyone.

For the next 48 hours, use code CYBER20 to redeem 20% off your first month of the Daily Synbiotic.

[manc10] 29/11/2020 00:20

Funding new ideas
Supported by Harvard Catalyst microbiome pilot funding over the past year through the Translational Innovator program, Gerber, Bry and Allegretti have been investigating whether a microbiome-focused clinical test can predict whose C. difficile infections will recur, which happens about 25 percent of the time. If identified, affected individuals can be given further treatment before infection sets in.

The researchers looked first at the microbiome using genetic sequencing and found they couldn’t make reliable predictions on that basis.

“But when we looked at the metabolites in the gut, both the substances produced by the host as well as microbial metabolites, we found we can predict pretty well whose infections will recur,” he said.

Larger studies need to verify the preliminary findings, and then human trials can begin.

Gerber credits Harvard Catalyst for providing pilot grants that have helped him get ideas off the ground, accelerating progress. Last year, he received a Brigham and Women’s President’s Scholar award, which comes with unrestricted funding, giving him the freedom to work on new projects of his choice.

“These kinds of programs are invaluable because they take a risk and fund ideas at earlier stages, or in new directions that wouldn’t be funded elsewhere,” he said.

Gerber is confident that with his collaborators he has the right mix of expertise for the challenges ahead.

“I’m super excited that we can begin to tie all the pieces together to make truly useful clinical predictions and interventions,”; he said.

Gerber’s research has been supported by grants from the National Institutes of Health, Defense Advanced Research Projects Agency and National Science Foundation.

[sentiment riles] 28/11/2020 22:56

Four hours coming for me too -

"In my favourite nation - where i dealt with most"